Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Reexamination Certificate
2005-04-14
2008-11-04
Saoud, Christine J (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
C435S069500, C435S007100, C435S335000
Reexamination Certificate
active
07446174
ABSTRACT:
The invention relates to novel proteins with TNF-α antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNF-α related disorders.
REFERENCES:
patent: 4677063 (1987-06-01), Mark et al.
patent: 4677064 (1987-06-01), Mark et al.
patent: 4879226 (1989-11-01), Wallace et al.
patent: 4894439 (1990-01-01), Dorin et al.
patent: 4948875 (1990-08-01), Tanaka et al.
patent: 4990455 (1991-02-01), Yamagishi et al.
patent: 5028420 (1991-07-01), Masegi et al.
patent: 5081021 (1992-01-01), Mizuno et al.
patent: 5151349 (1992-09-01), Tanaka et al.
patent: 5160483 (1992-11-01), Postlethwaite et al.
patent: 5180811 (1993-01-01), Doerper et al.
patent: 5262309 (1993-11-01), Nakamura et al.
patent: 5288852 (1994-02-01), Yamada et al.
patent: 5422104 (1995-06-01), Fiers et al.
patent: 5478925 (1995-12-01), Wallach et al.
patent: 5512544 (1996-04-01), Wallach et al.
patent: 5597899 (1997-01-01), Banner et al.
patent: 5606023 (1997-02-01), Chen et al.
patent: 5652353 (1997-07-01), Fiers et al.
patent: 5695953 (1997-12-01), Wallach et al.
patent: 5773582 (1998-06-01), Shin et al.
patent: 5888814 (1999-03-01), Kriegler et al.
patent: 5889156 (1999-03-01), Kriegler et al.
patent: 6188965 (2001-02-01), Mayo et al.
patent: 6269312 (2001-07-01), Mayo et al.
patent: 6403312 (2002-06-01), Dahiyat et al.
patent: 2001/0032052 (2001-10-01), Mayo et al.
patent: 2001/0039480 (2001-11-01), Mayo et al.
patent: 2002/0004706 (2002-01-01), Mayo et al.
patent: 2002/0009780 (2002-01-01), Dahiyat et al.
patent: 2002/0048772 (2002-04-01), Dahiyat et al.
patent: 2002/0090648 (2002-07-01), Dahiyat et al.
patent: 2002/0106694 (2002-08-01), Mayo et al.
patent: 2005051 (1990-06-01), None
patent: 0 254 647 (1988-01-01), None
patent: 0 486 908 (1992-05-01), None
patent: 0 251 037 (1994-06-01), None
patent: 0 251 037 (1998-07-01), None
patent: 60-252496 (1985-12-01), None
patent: 03-180194 (1991-08-01), None
patent: 03-297388 (1991-12-01), None
patent: 04-079880 (1992-03-01), None
patent: 04-182497 (1992-06-01), None
patent: 04-182498 (1992-06-01), None
patent: 04-368398 (1992-12-01), None
patent: 05-255393 (1993-10-01), None
patent: 05-271287 (1993-10-01), None
patent: 05-271289 (1993-10-01), None
patent: WO 90/07579 (1990-07-01), None
patent: WO 94/18325 (1994-08-01), None
patent: WO 98/47089 (1998-10-01), None
patent: WO 98/51344 (1998-11-01), None
patent: WO 00/23564 (2000-04-01), None
patent: WO 01/25277 (2001-04-01), None
patent: WO 01/59066 (2001-08-01), None
patent: WO 01/64889 (2001-09-01), None
Arakawa et al., “Alteration in folding efficiency and conformation of recombinant human tumor necrosis factor-alpha by replacing cysteines 69 and 101 aspartic acid 69 and arginine 101,” Protein Eng 3(8):721-724 (Aug. 1990).
Barbara et al., “Tumour necrosis factor-alpha (TNF-alpha): the good, the bad and potentially very effective,” Immunol Cell Biol 74(5):434-443 (Oct. 1996).
Cen et al., “Glycine68 to histidine73 has an important role in the function of human tumor necrosis factor alpha,” Biochem Mol Biol Int 43(1):47-52 (Sep. 1997).
Creasey et al., “Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines,” Cancer Res 47(1):14-149 (Jan. 1987).
Jones et al., “The three-dimensinal structure of tumour necrosis factor,” Prog Clin Biol Res 349:321-327 (1990).
Kinstler, O et al., “Mono-N-terminal poly(ethylene glycol)-protein conjugates,”Advanced Drug Delivery Reviews54:477-485 (2002).
Loetscher et al, “Human tumour necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors,” J Biol Chem 268(35):26350-26357 (Dec. 1993).
Masegi et al., “Characterization of a novel human tumor necrosis factor-alpha mutant with increased cytotoxic activity,” Jpn J Cancer Res 86(1):72-80 (Jan. 1995).
Narachi et al., “Role of single disulfide in recombinant human tumor necrosis factor-alpha,” J Biol Chem 262(27)13107-13110 (Sep. 1987).
Ngo, J.T. et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,”The Protein Folding Problem and Tertiary Structure Prediction, Merz, Jr. and Le Grand, Eds., Birkhauser, Boston 1994, pp. 492-495.
Peitsch, M.C. and Tschopp, J., “Comparative molecular modelling of the Fas-ligand and other members of the TNF family,” Mol Immunol. Jul. 1995;32(10):761-72.
Roberts, M.J. et al., “Chemistry for peptide and protein PEGylation,”Advanced Drug Delivery Reviews54:459-476 (2002).
Sato et al., “Differentiation induction by a tumor-necrosis-factor mutant 471 in human myelogenous leukemic cells via tumor-necrosis-factor receptor-p55,” Int J Cancer 78(2):223-232 (Oct. 1998).
Shin et al., “A novel tumor necrosis factor-alpha mutant with significantly enchanced cytotoxicity and receptor binding affinity,” Biochem Mol Biol Int 44(6):1075-1082 (May 1998).
Tavernier et al., “Analysis of the structure-function relationship of tumour necrosis factor. Human/mouse chimeric TNF proteins: general properties and epitope analysis,” J Mol Biol 211(2):493-501 (Jan. 1990).
Van Ostade, X., et al., “Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis,” EMBO J 10(4):827-836 (1991); Erratum in EMBO J 11(8):315 (1992).
Van Ostade et al., “Structure-activity studies of human tumour necrosis factors,” Protein Eng 7(1):5-22 (Jan. 1994).
Van Ostade et al., “Two conserved tryptophan residues of tumor necrosis factor and lymphotoxin are not involved in the biological activity,” FEBS Lett 238(2):347-352 (Oct. 1988).
Van Ostade, “Human TNF mutants with selective activity on the p55 receptor,” Nature 361:266-269 (Jan. 1993).
Watson, “TNF inhibitors: A review of the recent patent literature”, Drugs, 2002, 5(12):1151-1161.
Wells, J.A., “Additivity of Mutational Effects in Proteins,”Biochemistry26(37):8509-8517 (1990).
Xi et al., “Biological activities of human tumor necrosis factor-alpha and its novel mutants,” Biochem Mol Biol Int 38(4):855-862 (Apr. 1996).
Xi et al., “Biological activities of human tumor necrosis factor-alpha and its novel mutants,” Biochem Mol Biol Int 38(6):1183-1189 (May 1996).
Yamagishi et al., “Mutational analysis of structure—activity relationships in human tumor necrosis factor-alpha,” Protein Engineering 3(8):713-719 (1990).
Yamamoto et al., “Histidine-15: an important role in the cytotoxic activity of human tumor necrosis factor,” Protein Eng 2(7):553-558 (May 1989).
Zhang et al., “Site-directed mutational analysis of human tumor necrosis factor-alpha receptor binding site and structure-functional relationship,” J Biol Chem 267(33):24069-24075 (Nov. 1992).
Desjarlais John R.
Steed Paul Michael
Szymkowski David Edmund
Zalevsky Jonathan
Foster, Esq. David C.
Morgan & Lewis & Bockius, LLP
Saoud Christine J
Seharaseyon Jegatheesan
Silva, Esq. Robin M.
LandOfFree
Protein based TNF-α variants for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protein based TNF-α variants for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein based TNF-α variants for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4049685